You have 9 free searches left this month | for more free features.

deferasirox:

Showing 1 - 25 of 54

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Measures to Prevent Liver and Pancreas Complications in

Active, not recruiting
  • Iron Overload
  • Trieste, Italy
    IRCCS Burlo Garofolo
Jan 4, 2022

Beta-thalassemia, Iron Overload Trial in Los Angeles, Oakland, Chicago (Deferasirox)

Completed
  • Beta-thalassemia
  • Iron Overload
  • Los Angeles, California
  • +2 more
Jun 8, 2021

MDS, Iron Overload Trial in Stanford, Detroit, Houston (Deferasirox)

Completed
  • Myelodysplastic Syndromes
  • Iron Overload
  • Stanford, California
  • +2 more
Jun 1, 2021

Transfusional Iron Overload, Iron Overload, Iron Chelation Trial (SPD602, Deferasirox)

Withdrawn
  • Transfusional Iron Overload
  • +6 more
  • (no location specified)
Jun 1, 2021

Hepatic Impairment Trial in Kiel (Deferasirox)

Completed
  • Hepatic Impairment
  • Kiel, Germany
    Novartis Investigative Site
Dec 6, 2020

ß-thalassemia, Transfusional Iron Overload Trial in Cagliari, Genova, Orbassano (Deferasirox)

Completed
  • β-thalassemia
  • Transfusional Iron Overload
  • Cagliari, CA, Italy
  • +2 more
Dec 6, 2020

Chronic Iron Overload Trial in Worldwide (Deferiprone, Deferasirox)

Completed
  • Chronic Iron Overload
  • Lushnjë, Albania
  • +21 more
Apr 8, 2021

Anemia, Myelodysplastic Syndrome Trial in Seattle (Deferasirox, Laboratory Biomarker Analysis)

Terminated
  • Anemia
  • Myelodysplastic Syndrome
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 12, 2020

Myelodysplastic Syndrome, Iron Overload Trial in Canada, United States (Deferasirox)

Completed
  • Myelodysplastic Syndrome
  • Iron Overload
  • Birmingham, Alabama
  • +47 more
Jul 21, 2021

Acute Myeloid Leukemia Trial in Maywood (Deferasirox, Cholecalciferol, Azacitidine)

Terminated
  • Acute Myeloid Leukemia
  • Maywood, Illinois
    Loyola University Cardinal Bernardin Cancer Center
Feb 25, 2020

Chronic Iron Overload Trial in Austria, Greece, Italy (Deferasirox)

Completed
  • Chronic Iron Overload
  • Vienna, Austria
  • +13 more
Feb 18, 2020

Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))

Terminated
  • Transfusion-dependent β-thalassemia Patients
  • Cardiac Iron Overload
  • Athens, GR, Greece
  • +3 more
Oct 21, 2019

Non-transfusion Dependent Thalassemia Trial in Worldwide (deferasirox)

Completed
  • Non-transfusion Dependent Thalassemia
  • Nanning, Guangxi, China
  • +10 more
Sep 19, 2019

Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease Trial in Boston (Deferoxamine, Deferasirox, HIDA)

Completed
  • Transfusion-dependent Hemachromatosis
  • +2 more
  • Boston, Massachusetts
    Children's Hospital Boston
Jun 14, 2019

MDS Trial in Worldwide (Deferasirox, Placebo)

Completed
  • Myelodysplastic Syndromes
  • Anaheim, California
  • +71 more
Oct 30, 2020

MDS Trial in Italy (Deferasirox)

Unknown status
  • Myelodysplastic Syndromes
  • Firenze, FI, Italy
  • +9 more
Jul 15, 2019

Transfusion-dependent Iron Overload Trial in Worldwide (Deferasirox)

Completed
  • Transfusion-dependent Iron Overload
  • Adelaide, Australia
  • +97 more
Feb 8, 2020

Myelodysplastic Syndrome Trial in Liege (Bone marrow aspirate, Deferasirox)

Terminated
  • Myelodysplastic Syndrome
  • Liege, Belgium
    Novartis Investigative Site
Jul 24, 2018

Breast Cancer, Iron Overload, Leukemia Trial in Minneapolis (deferasirox)

Terminated
  • Breast Cancer
  • +7 more
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Dec 3, 2017

Beta-thalassemia, MDS, Fanconi Syndrome Trial in United States (Deferasirox)

Completed
  • Beta-thalassemia
  • +4 more
  • Oakland, California
  • +5 more
Aug 17, 2017

Thalassemia (Transfusion Delendent) Trial (deferasirox)

Withdrawn
  • Thalassemia (Transfusion Delendent)
  • (no location specified)
Apr 19, 2017

Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD Trial (Deferasirox)

Withdrawn
  • Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
  • (no location specified)
Apr 19, 2017

ß-thalassemia Major Trial (Deferasirox)

Withdrawn
  • β-thalassemia Major
  • (no location specified)
Apr 19, 2017

MDS, Beta-Thalassemia Trial in Hungary (deferasirox)

Completed
  • Myelodysplastic Syndromes
  • Beta-Thalassemia
  • Budapest, Hungary
  • +3 more
Feb 22, 2017